GlassScriptPhysician profile
Amber Willmoth-Miller
NPI 1972176857
$1,427.53
in general payments reported to CMS, 2019-2025
12 companies · $1,047 in 2025
The $1,047 reported for 2025 was more than what 81% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $230 · 2024: $150 · 2025: $1,047.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,197.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $459.40 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $356.03 | 2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Teva Pharmaceuticals USA, INC. | $231.55 | 2022-2025 | Austedo Xr |
| Alkermes, INC. | $133.14 | 2022-2024 | Aristada, Lybalvi |
| Luye Pharma (USA) LTD. | $109.09 | 2025 | Erzofri Extended-Release |
| Janssen Pharmaceuticals, INC | $31.04 | 2024-2025 | Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $20.23 | 2025 | |
| Axsome Therapeutics, INC. | $19.73 | 2024 | Auvelity |
| Indivior INC. | $19.15 | 2024 | Sublocade |
| Lundbeck LLC | $17.74 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $16.94 | 2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.49 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Willmoth-Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.